EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Comparisons

Which current developments change the comparison?

Dose Diligence research deskSection 03 · Page 3 of 12Last updated 17 Nov 2026

Do not reuse a shortage-era supplier assessment or a 2025 programme-price spreadsheet without updating it. The following developments materially affect the procurement questions to ask.

Verified developmentProcurement implication
FDA's GLP-1 clarification states that semaglutide and tirzepatide are not on the 503B bulks list or its drug-shortage list; the retrieved shortage index does not list their injections as currently in shortage.Do not treat historical shortage arrangements as the default basis for new commitments. Check the exact product and status again before contracting. (fda.gov)
The Fifth Circuit affirmed the judgments supporting FDA's tirzepatide and semaglutide shortage decisions on August 27, 2026; the retrieved semaglutide opinion was revised September 1, 2026.A statement that litigation automatically preserves shortage-era supply requires current, case-specific evidence. These opinions do not replace assessment of individual compounding arrangements. (govinfo.gov)
FDA announced a proposal on April 30, 2026 not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list.Distinguish the proposal from existing restrictions. A final determination was not verified in the official material retrieved for this report; do not describe the proposal itself as a final rule. (fda.gov)
California introduced additional nonresident-pharmacy requirements effective July 1, 2026, including designation of a California-licensed pharmacist-in-charge for California operations.Refresh destination-state evidence rather than relying on an old national-coverage spreadsheet. (pharmacy.ca.gov)
FDA's current DSCSA page extends specified exemptions for qualifying small dispensers to November 27, 2027.Do not use an obsolete blanket November 2026 deadline. Determine the entity's role, eligibility and the specific requirements covered. (fda.gov)
FDA announced GLP-1 safety-labelling changes on November 9, 2026, concerning a potential increased risk of non-arteritic anterior ischemic optic neuropathy, a rare serious eye condition.Require clinical leadership and partners to maintain current counselling, safety communications and escalation procedures. This is not a procurement-led reason to switch treatment. (fda.gov)

Outstanding legal verification: This review located the appellate opinions and FDA materials above, but did not establish a complete subsequent litigation docket or every later administrative action. Obtain a dated, product-specific legal assessment before relying on a disputed supply theory.

Explore the table row by row

A working view of the research

FDA's GLP-1 clarification states that semaglutide and tirzepatide are not on the 503B bulks list or its drug-shortage list; the retrieved shortage index does not list their injections as currently in shortage.

Procurement implication
Do not treat historical shortage arrangements as the default basis for new commitments. Check the exact product and status again before contracting. (fda.gov)

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  2. govinfo.gov · Source 2 ↗https://www.govinfo.gov/content/pkg/USCOURTS-ca5-25-10600/pdf/USCOURTS-ca5-25-10600-0.pdf
  3. fda.gov · Source 3 ↗https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list?utm_source=openai
  4. pharmacy.ca.gov · Source 4 ↗https://www.pharmacy.ca.gov/applicants/new_requirements_nrp.shtml
  5. fda.gov · Source 5 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  6. fda.gov · Source 6 ↗https://www.fda.gov/drugs/drug-safety-communications/fda-requires-safety-labeling-changes-glucagon-peptide-1-receptor-agonists-glp-1-ras-due-potential?trk=public_post_comment-text
Section sources →